stoxline Quote Chart Rank Option Currency Glossary
AbbVie Inc. (ABBV)
166.41  1.75 (1.06%)    04-19 16:00
Open: 165.02
High: 166.6
Volume: 5,526,776
Pre. Close: 164.66
Low: 163.25
Market Cap: 294,654(M)
Technical analysis
2024-04-19 5:07:29 PM
Short term     
Mid term     
Targets 6-month :  202.97 1-year :  212.92
Resists First :  173.78 Second :  182.3
Pivot price 168.99
Supports First :  160 Second :  133.11
MAs MA(5) :  163.9 MA(20) :  171.67
MA(100) :  166.34 MA(250) :  153.26
MACD MACD :  -3.5 Signal :  -2.8
%K %D K(14,3) :  23 D(3) :  17.6
RSI RSI(14): 39.7
52-week High :  182.88 Low :  130.96
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ ABBV ] has closed above bottom band by 39.2%. Bollinger Bands are 100.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 10 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 166.62 - 167.2 167.2 - 167.73
Low: 161.57 - 162.32 162.32 - 163.01
Close: 165.21 - 166.27 166.27 - 167.23
Company Description

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Headline News

Thu, 18 Apr 2024
AbbVie buyout Cerevel marks trial win for Parkinson's drug - Seeking Alpha

Wed, 17 Apr 2024
AbbVie (ABBV) Increases Despite Market Slip: Here's What You Need to Know - Yahoo Finance

Wed, 17 Apr 2024
Medincell and AbbVie enter injectable therapy development deal - Pharmaceutical Technology

Tue, 16 Apr 2024
AbbVie Inc. stock outperforms competitors on strong trading day - MarketWatch

Tue, 16 Apr 2024
AbbVie: Through Humira's Crisis Towards Solid Growth (NYSE:ABBV) - Seeking Alpha

Tue, 16 Apr 2024
Fake Botox Fight Sends AbbVie (NASDAQ:ABBV) Up Fractionally - - TipRanks

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Drug Manufacturers - General
Shares Out 1,770 (M)
Shares Float 1,760 (M)
Held by Insiders 0.1 (%)
Held by Institutions 71.9 (%)
Shares Short 13,120 (K)
Shares Short P.Month 14,270 (K)
Stock Financials
EPS 2.73
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 5.86
Profit Margin 8.9 %
Operating Margin 31.8 %
Return on Assets (ttm) 8 %
Return on Equity (ttm) 35.2 %
Qtrly Rev. Growth -5.5 %
Gross Profit (p.s.) 0
Sales Per Share 30.68
EBITDA (p.s.) 14.89
Qtrly Earnings Growth -67 %
Operating Cash Flow 22,840 (M)
Levered Free Cash Flow 22,630 (M)
Stock Valuations
PE Ratio 60.95
PEG Ratio 2.3
Price to Book value 28.34
Price to Sales 5.42
Price to Cash Flow 12.89
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android